Overview

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Vildagliptin